Yes

Anorexiant

Short-term adjunct in a regimen of weight reduction based on exercise, behavioral modification, and caloric reduction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m² or greater than or equal to 27 kg/m² in the presence of other risk factors (diabetes, hypertension)

5'0"

140 lb: BMI = 27

150 lb: BMI = 29

160 lb: BMI = 31

170 lb: BMI = 33

180 lb: BMI = 35

190 lb: BMI = 37

200 lb: BMI = 39

210 lb: BMI = 41

220 lb: BMI = 43

230 lb: BMI = 45

240 lb: BMI = 47

250 lb: BMI = 49

5'3"

140 lb: BMI = 25

150 lb: BMI = 27

160 lb: BMI = 28

170 lb: BMI = 30

180 lb: BMI = 32

190 lb: BMI = 34

200 lb: BMI = 36

210 lb: BMI = 37

220 lb: BMI = 39

230 lb: BMI = 41

240 lb: BMI = 43

250 lb: BMI = 44

5'6"

140 lb: BMI = 23

150 lb: BMI = 24

160 lb: BMI = 26

170 lb: BMI = 28

180 lb: BMI = 29

190 lb: BMI = 31

200 lb: BMI = 32

210 lb: BMI = 34

220 lb: BMI = 36

230 lb: BMI = 37

240 lb: BMI = 39

250 lb: BMI = 40

5'9"

140 lb: BMI = 21

150 lb: BMI = 22

160 lb: BMI = 24

170 lb: BMI = 25

180 lb: BMI = 27

190 lb: BMI = 28

200 lb: BMI = 30

210 lb: BMI = 31

220 lb: BMI = 33

230 lb: BMI = 34

240 lb: BMI = 36

250 lb: BMI = 37

6'0"

140 lb: BMI = 19

150 lb: BMI = 20

160 lb: BMI = 22

170 lb: BMI = 23

180 lb: BMI = 25

190 lb: BMI = 26

200 lb: BMI = 27

210 lb: BMI = 29

220 lb: BMI = 30

230 lb: BMI = 31

240 lb: BMI = 33

250 lb: BMI = 34

6'3"

140 lb: BMI = 18

150 lb: BMI = 19

160 lb: BMI = 20

170 lb: BMI = 21

180 lb: BMI = 23

190 lb: BMI = 24

200 lb: BMI = 25

210 lb: BMI = 26

220 lb: BMI = 28

230 lb: BMI = 29

240 lb: BMI = 30

250 lb: BMI = 31

Unlabeled uses: Migraine

C-IV

B

Known hypersensitivity or idiosyncrasy to sympathomimetic amines. Patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension (stage II or III), hyperthyroidism, glaucoma, agitated states, patients with a history of drug abuse, and during or within 14 days following MAO inhibitor therapy. Concurrent use with other anorectic agents; stimulant medications are contraindicated for use in children with attention deficit/hyperactivity disorders and concomitant Tourette's syndrome or tics.

Use with caution in patients with bipolar disorder, diabetes mellitus, cardiovascular disease, seizure disorders, insomnia, porphyria, or mild hypertension (stage I). May exacerbate symptoms of behavior and thought disorder in psychotic patients. Potential for drug dependency exists - avoid abrupt discontinuation in patients who have received for prolonged periods. Stimulant use in children has been associated with growth suppression. Not recommended for use in patients < 12 years of age.

Cardiovascular: Hypertension, palpitations, tachycardia, chest pain, T-wave changes, arrhythmias, pulmonary hypertension, valvalopathy

Central nervous system: Euphoria, nervousness, insomnia, restlessness, dizziness, anxiety, headache, agitation, confusion, mental depression, psychosis, CVA, seizure

Dermatologic: Alopecia, urticaria, skin rash, ecchymosis, erythema

Endocrine & metabolic: Changes in libido, gynecomastia, menstrual irregularities, porphyria

Gastrointestinal: Nausea, vomiting, abdominal cramps, constipation, xerostomia, metallic taste

Genitourinary: Impotence

Hematologic: Bone marrow depression, agranulocytosis, leukopenia

Neuromuscular & skeletal: Tremor

Ocular: Blurred vision, mydriasis

There is no specific antidote for amphetamine intoxication and the bulk of the treatment is supportive. Hyperactivity and agitation usually respond to reduced sensory input; however, with extreme agitation, haloperidol (2-5 mg I.M. for adults) may be required. Hyperthermia is best treated with external cooling measures, or when severe or unresponsive, muscle paralysis with pancuronium may be needed. Hypertension is usually transient and generally does not require treatment unless severe. For diastolic blood pressures >110 mm Hg, a nitroprusside infusion should be initiated. Seizures usually respond to diazepam I.V. and/or phenytoin maintenance regimens.

Diethylpropion may displace guanethidine from the neuron and antagonize its antihypertensive effects; discontinue diethylpropion or use alternative antihypertensive

Concurrent use or use within 14 days following the administration of a MAOI is contraindicated (hypertensive crisis)

Concurrent use of sibutramine and diethylpropion is contraindicated (severe hypertension, tachycardia)

Concurrent use with TCA may result in hypertension and CNS stimulation; best to avoid this combination

Concurrent use with other anorectic agents may cause serious cardiac problems and is contraindicated

Diethylpropion is used as an anorexiant agent possessing pharmacological and chemical properties similar to those of amphetamines. The mechanism of action of diethylpropion in reducing appetite appears to be secondary to CNS effects, specifically stimulation of the hypothalamus to release catecholamines into the central nervous system; anorexiant effects are mediated via norepinephrine and dopamine metabolism. An increase in physical activity and metabolic effects (inhibition of lipogenesis and enhancement of lipolysis) may also contribute to weight loss.

Onset of action: 1 hour

Duration: 12-24 hours

Adults: Oral:

Tablet, controlled release: 75 mg at midmorning

Alcohol: Avoid use

Monitor CNS

Insomnia, nervousness, and euphoria are common; may cause confusion, depression, or psychosis

Concurrent use with MAOIs may cause hypertensive crisis; avoid combination; antipsychotics may blunt effect of diethylpropion. May cause bone marrow depression; use caution with clozapine.

Use vasoconstrictor with caution in patients taking diethylpropion. Amphetamine-like drugs such as diethylpropion enhance the sympathomimetic response of epinephrine and norepinephrine leading to potential hypertension and cardiotoxicity.

Up to 10% of patients may present with hypertension. The use of local anesthetic without vasoconstrictor is recommended in these patients.

Take exactly as directed (do not increase dose or frequency without consulting prescriber); may cause physical and/or psychological dependence. Do not crush or chew extended release tablets. Take early in day to avoid sleep disturbance, 1 hour before meals. Avoid alcohol, caffeine, or OTC medications that act as stimulants. You may experience restlessness, false sense of euphoria, or impaired judgment (use caution when driving or engaging in tasks requiring alertness until response to drug is known); dry mouth (frequent mouth care, sucking lozenges, or chewing gum may help); nausea or vomiting (small frequent meals, frequent mouth care may help); constipation (increased exercise, dietary fiber, fruit, or fluid may help); diarrhea (buttermilk, boiled milk, or yogurt may help); or altered libido (reversible). Diabetics need to monitor serum glucose closely (may alter antidiabetic medication requirements). Report chest pain, palpitations, or irregular heartbeat; muscle weakness or tremors; extreme fatigue or depression; CNS changes (aggressiveness, restlessness, euphoria, sleep disturbances); severe unremitting abdominal distress or cramping; changes in sexual activity; changes in urinary pattern; or blurred vision. Breast-feeding precautions: Breast-feeding is not recommended.

Do not crush 75 mg controlled release tablets; dose should not be given in evening or at bedtime

Tablet, as hydrochloride: 25 mg

Tablet, as hydrochloride, controlled release: 75 mg